EQS-News: More Impact AG: Patent granted in the US for innovative Speedinject technology
|
EQS-News: More Impact AG
/ Key word(s): Patent
More Impact AG: Patent granted in the US for innovative Speedinject technology Frankfurt/Main, May 20, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, has announced that a patent has been granted in the United States for its Speedinject needle-free injection technology. Speedinject was developed by More Impact subsidiary The Key Unternehmensberatung GmbH (“The Key”). This marks another important step forward in the company's internationalization strategy. Speedinject’s technological innovation enables active ingredients to be administered without needles. The technology is ideal, for example, for administering drugs for diabetes and weight loss and has been tailored to the requirements of the US market, among others. There is growing demand in the US for effective, patient-friendly, and environmentally friendly solutions, particularly in obesity treatment. The More Impact subsidiary is thus addressing a rapidly growing future market in the pharmaceutical sector. According to current market analyses, the average annual growth rate (CAGR) for weight loss injections worldwide is expected to exceed 18% (2023-2030). Speedinject uses an electromagnetically driven system for intramuscular injection and completely dispenses with conventional needles. The system offers a precise, painless, and hygienic solution and leaves behind hardly any waste except for a recyclable glass cartridge. A biodegradable cartridge variant is already in development. The technology, which has now been granted a US patent, is particularly well suited for patients with needle phobia or chronic injection needs and also offers a sustainable alternative to conventional prefilled syringes, which generate large amounts of hazardous waste. About More Impact AG More Impact AG is a listed high-tech medical hub that specializes in the development and support of innovative companies in the medical field. With a focus on securing patents and commercializing product innovations, More Impact contributes to making cutting-edge MedTech technologies accessible to a broad part of the population and sustainably improving global healthcare. Strategic acquisitions and divestitures of companies, divisions or individual patents round off the business model. Contact – Investor & Media Relations
20.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
| Language: | English |
| Company: | More Impact AG |
| Mörfelder Landstraße 277 b | |
| 60598 Frankfurt | |
| Germany | |
| Phone: | +49 69 38076661 |
| E-mail: | info@moreimpactag.de |
| Internet: | https://moreimpactag.de |
| ISIN: | DE000A1PG979, DE000A40ZTM3 |
| WKN: | A1PG97 |
| Listed: | Regulated Unofficial Market in Dusseldorf |
| EQS News ID: | 2141722 |
| End of News | EQS News Service |
|
|
2141722 20.05.2025 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | ||
| Sales1 | 0,00 | 0,00 | 0,00 | 0,00 | 0,10 | 0,00 | 0,00 | |
| EBITDA1,2 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 0,00 | 0,00 | 0,00 | 0,00 | -370,00 | 0,00 | 0,00 | |
| EBIT1,4 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| EBIT-Margin5 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | 0,00 | 0,00 | -0,81 | 0,00 | 0,00 | |
| Net-Margin6 | 0,00 | 0,00 | 0,00 | 0,00 | -810,00 | 0,00 | 0,00 | |
| Cashflow1,7 | 0,00 | 0,00 | 0,00 | 0,00 | -0,37 | 0,00 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | 0,00 | 0,00 | -0,01 | -0,02 | -0,02 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Nexia
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| More Impact | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A1PG97 | DE000A1PG979 | AG | 391,53 Mio € | 30.07.2012 | Halten | 9F2C3MM7+X6 |
| PE 2026e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 30,00 | 0,00 | 0,00 | -75,00 | 5,59 | -1.069,76 | 3.954,87 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 29.08.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -8,42% | -29,08% | +50,75% | +50,00% | +20,00% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
